Joseph F Gera

Title(s)Adjunct Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    Co-targeting mTOR and YAP signaling in glioblastoma
    NIH R01CA217820Apr 1, 2018 - Mar 31, 2023
    Role: Principal Investigator
    Mechanisms of Resistance to mTOR Targeted Therapies
    NIH I01BX002665Jul 1, 2014 - Jun 30, 2022
    Role: Principal Investigator
    Dysregulation of mTORC2 in gliomas
    NIH R01CA168700Jul 17, 2012 - Apr 30, 2017
    Role: Principal Investigator
    Regulation of c-myc translation by hnRNP A1: role in multiple myeloma tumor respo
    NIH R01CA132778Jul 1, 2008 - May 31, 2015
    Role: Principal Investigator
    Mechanisms of Akt-dependent sensitivity to rapamycin
    NIH R01CA109312Jun 1, 2004 - May 31, 2014
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A lupus-derived autoantibody that binds to intracellular RNA activates cGAS-mediated tumor immunity and can deliver RNA into cells. Sci Signal. 2025 Mar 25; 18(879):eadk3320. Chen X, Tang X, Xie Y, Cuffari BJ, Tang C, Cao F, Gao X, Meng Z, Noble PW, Young MR, Turk OM, Shirali A, Gera J, Nishimura RN, Zhou J, Hansen JE. PMID: 40132052; PMCID: PMC12076517.
      View in: PubMed   Mentions:    Fields:    
    2. Cellular protection from H2O2 toxicity by Fv-Hsp70: protection via catalase and gamma-glutamyl-cysteine synthase. Cell Stress Chaperones. 2023 07; 28(4):429-439. Hino C, Chan G, Jordaan G, Chang SS, Saunders JT, Bashir MT, Hansen JE, Gera J, Weisbart RH, Nishimura RN. PMID: 37171750; PMCID: PMC10352194.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET. J Neurooncol. 2023 May; 163(1):207-218. Saunders JT, Kumar S, Benavides-Serrato A, Holmes B, Benavides KE, Bashir MT, Nishimura RN, Gera J. PMID: 37162666; PMCID: PMC10232650.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    4. m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition. Cancer Lett. 2023 05 28; 562:216178. Benavides-Serrato A, Saunders JT, Kumar S, Holmes B, Benavides KE, Bashir MT, Nishimura RN, Gera J. PMID: 37061119; PMCID: PMC10805108.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    5. Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Mol Cancer Ther. 2022 04 01; 21(4):502-510. Shi Y, Sun F, Cheng Y, Holmes B, Dhakal B, Gera JF, Janz S, Lichtenstein A. PMID: 35086951; PMCID: PMC8983490.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    6. Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation. J Biol Chem. 2022 04; 298(4):101750. Vega M, Chen Y, Shi Y, Gera J, Lichtenstein A. PMID: 35216969; PMCID: PMC8933699.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    7. Hypocretin/Orexin Interactions with Norepinephrine Contribute to the Opiate Withdrawal Syndrome. J Neurosci. 2022 01 12; 42(2):255-263. McGregor R, Wu MF, Holmes B, Lam HA, Maidment NT, Gera J, Yamanaka A, Siegel JM. PMID: 34853083; PMCID: PMC8802943.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    8. mTORC2-mediated direct phosphorylation regulates YAP activity promoting glioblastoma growth and invasive characteristics. Neoplasia. 2021 09; 23(9):951-965. Holmes B, Benavides-Serrato A, Saunders JT, Kumar S, Nishimura RN, Gera J. PMID: 34343821; PMCID: PMC8347669.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    9. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma. J Neurooncol. 2021 Apr; 152(2):217-231. Saunders JT, Holmes B, Benavides-Serrato A, Kumar S, Nishimura RN, Gera J. PMID: 33511508; PMCID: PMC8005474.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    10. Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma. Int J Mol Sci. 2020 Jan 05; 21(1). Benavides-Serrato A, Saunders JT, Holmes B, Nishimura RN, Lichtenstein A, Gera J. PMID: 31948038; PMCID: PMC6981868.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    11. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. J Neurooncol. 2019 Oct; 145(1):11-22. Holmes B, Benavides-Serrato A, Saunders JT, Landon KA, Schreck AJ, Nishimura RN, Gera J. PMID: 31473880; PMCID: PMC6776692.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    12. A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity. Mol Cancer Ther. 2019 10; 18(10):1822-1831. Vega MI, Shi Y, Frost P, Huerta-Yepez S, Antonio-Andres G, Hernandez-Pando R, Lee J, Jung ME, Gera JF, Lichtenstein A. PMID: 31395691; PMCID: PMC6774835.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    13. Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction. Bioorg Med Chem Lett. 2017 10 15; 27(20):4714-4724. Lee J, Shi Y, Vega M, Yang Y, Gera J, Jung ME, Lichtenstein A. PMID: 28916338.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    14. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma. PLoS One. 2017; 12(4):e0176599. Benavides-Serrato A, Lee J, Holmes B, Landon KA, Bashir T, Jung ME, Lichtenstein A, Gera J. PMID: 28453552; PMCID: PMC5409528.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    15. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. Cancer Res. 2016 10 01; 76(19):5822-5831. Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A. PMID: 27530328; PMCID: PMC5100807.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    16. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma. J Biol Chem. 2016 Jul 01; 291(27):14146-14159. Holmes B, Lee J, Landon KA, Benavides-Serrato A, Bashir T, Jung ME, Lichtenstein A, Gera J. PMID: 27226604; PMCID: PMC4933173.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    17. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness. J Biol Chem. 2015 Aug 07; 290(32):19387-401. Artinian N, Cloninger C, Holmes B, Benavides-Serrato A, Bashir T, Gera J. PMID: 25998128; PMCID: PMC4528104.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    18. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer. 2014 Nov; 5(11-12):407-19. Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, Gera J, Lichtenstein A. PMID: 25568666; PMCID: PMC4279438.
      View in: PubMed   Mentions: 13  
    19. mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma. Genes Cancer. 2014 Nov; 5(11-12):393-406. Benavides-Serrato A, Anderson L, Holmes B, Cloninger C, Artinian N, Bashir T, Gera J. PMID: 25568665; PMCID: PMC4279437.
      View in: PubMed   Mentions: 16  
    20. MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses. PLoS One. 2014; 9(4):e94011. Shi Y, Frost P, Hoang B, Yang Y, Bardeleben C, Gera J, Lichtenstein A. PMID: 24714040; PMCID: PMC3979714.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    21. Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol. 2013; 2013:897025. Frost P, Berlanger E, Mysore V, Hoang B, Shi Y, Gera J, Lichtenstein A. PMID: 23533410; PMCID: PMC3603547.
      View in: PubMed   Mentions: 19  
    22. Targeting cancer with a lupus autoantibody. Sci Transl Med. 2012 Oct 24; 4(157):157ra142. Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. PMID: 23100628; PMCID: PMC3713477.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    23. Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One. 2012; 7(10):e47741. Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, Holmes B, Benavides-Serrato A, Sabha N, Nishimura RN, Guha A, Gera J. PMID: 23077666; PMCID: PMC3471885.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    24. A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets. Mol Cancer Ther. 2012 Oct; 11(10):2169-73. Weisbart RH, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ, Nishimura RN. PMID: 22863609.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    25. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem. 2012 Jun 22; 287(26):21796-805. Hoang B, Benavides A, Shi Y, Yang Y, Frost P, Gera J, Lichtenstein A. PMID: 22556409; PMCID: PMC3381142.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    26. Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress. Cell Signal. 2012 Jan; 24(1):309-15. Holmes B, Artinian N, Anderson L, Martin J, Masri J, Cloninger C, Bernath A, Bashir T, Benavides-Serrato A, Gera J. PMID: 21964062; PMCID: PMC3205320.
      View in: PubMed   Mentions: 9     Fields:    
    27. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov. 2011 Nov; 1(6):524-38. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. PMID: 22145100; PMCID: PMC3229221.
      View in: PubMed   Mentions: 172     Fields:    
    28. Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Mol Cancer Ther. 2011 Dec; 10(12):2244-56. Cloninger C, Bernath A, Bashir T, Holmes B, Artinian N, Ruegg T, Anderson L, Masri J, Lichtenstein A, Gera J. PMID: 21911485; PMCID: PMC3237929.
      View in: PubMed   Mentions: 19     Fields:    
    29. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk Lymphoma. 2011 Oct; 52(10):1857-66. Gera J, Lichtenstein A. PMID: 21599581.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    30. Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity. J Biol Chem. 2011 May 06; 286(18):16402-13. Martin J, Masri J, Cloninger C, Holmes B, Artinian N, Funk A, Ruegg T, Anderson L, Bashir T, Bernath A, Lichtenstein A, Gera J. PMID: 21454539; PMCID: PMC3091246.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    31. AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation. Mol Cancer Res. 2011 Jan; 9(1):115-30. Vartanian R, Masri J, Martin J, Cloninger C, Holmes B, Artinian N, Funk A, Ruegg T, Gera J. PMID: 21135252; PMCID: PMC3105464.
      View in: PubMed   Mentions: 36     Fields:    
    32. IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. J Biol Chem. 2011 Jan 07; 286(1):67-78. Shi Y, Frost P, Hoang B, Benavides A, Gera J, Lichtenstein A. PMID: 20974848; PMCID: PMC3013026.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    33. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood. 2010 Nov 25; 116(22):4560-8. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, Cappia S, Guglielmelli T, Gera J, Lichtenstein A. PMID: 20686120; PMCID: PMC2996116.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    34. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol Cancer Ther. 2009 Jan; 8(1):83-93. Frost P, Shi Y, Hoang B, Gera J, Lichtenstein A. PMID: 19139116; PMCID: PMC2651087.
      View in: PubMed   Mentions: 13     Fields:    
    35. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res. 2008 Dec 15; 68(24):10215-22. Shi Y, Frost PJ, Hoang BQ, Benavides A, Sharma S, Gera JF, Lichtenstein AK. PMID: 19074889; PMCID: PMC2701383.
      View in: PubMed   Mentions: 28     Fields:    
    36. Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling. J Biol Chem. 2008 Aug 22; 283(34):23274-87. Jo OD, Martin J, Bernath A, Masri J, Lichtenstein A, Gera J. PMID: 18562319; PMCID: PMC2516998.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    37. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun. 2008 Aug 08; 372(4):578-83. Martin J, Masri J, Bernath A, Nishimura RN, Gera J. PMID: 18505677; PMCID: PMC2512964.
      View in: PubMed   Mentions: 30     Fields:    
    38. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007 Dec 15; 67(24):11712-20. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J. PMID: 18089801.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCells
    39. Protein kinase C regulates internal initiation of translation of the GATA-4 mRNA following vasopressin-induced hypertrophy of cardiac myocytes. J Biol Chem. 2007 Mar 30; 282(13):9505-9516. Sharma A, Masri J, Jo OD, Bernath A, Martin J, Funk A, Gera J. PMID: 17284439.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    40. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 2006 Feb 15; 66(4):2305-13. Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A. PMID: 16489035.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    41. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005 Oct; 4(10):1533-40. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. PMID: 16227402.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansAnimalsCells
    42. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem. 2005 Mar 25; 280(12):10964-73. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. PMID: 15634685.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    43. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004 Dec 15; 104(13):4181-7. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A. PMID: 15304393.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimals
    44. Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene. 2004 Apr 22; 23(19):3368-75. Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, Gera J, Lichtenstein A. PMID: 15021914.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    45. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004 Jan 23; 279(4):2737-46. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. PMID: 14576155.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCells
    46. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells. Mol Cancer Ther. 2003 Jun; 2(6):563-72. Shi Y, Gera J, Hsu JH, Van Ness B, Lichtenstein A. PMID: 12813136.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    47. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003 Apr 15; 101(8):3126-35. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. PMID: 12515720.
      View in: PubMed   Mentions: 34     Fields:    Translation:Cells
    48. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002 Sep 01; 62(17):5027-34. Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A. PMID: 12208757.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    49. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem. 2002 May 03; 277(18):15712-20. Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. PMID: 11872747.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    50. Array-based methods for identifying protein-protein and protein-nucleic acid interactions. Methods Enzymol. 2002; 350:499-512. Gera JF, Hazbun TR, Fields S. PMID: 12073332.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    Joseph's Networks
    Concepts (240)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California